ELLEX: A GLOBAL LEADER IN RESTORATIVE GLAUCOMA THERAPY

Tom Spurling, CEO Ellex Medical
(Australian Securities Exchange, ELX)

Oppenheimer 28th Annual Healthcare Conference
New York City, 20 March 2018
DISCLAIMER

This presentation has been prepared by Ellex Medical (Ellex, ELX: ASX). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statement. These forward-looking statement have been made based upon Ellex’s expectations and beliefs concerning future developments and their potential effect on Ellex (and it’s controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Ellex’s control. No assurance is given that future developments will be in accordance with Ellex’s expectations. Actual results could differ materially from those expected by Ellex. This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.
## ELLEX MEDICAL CORPORATE SUMMARY

<table>
<thead>
<tr>
<th>Exchange</th>
<th>Australian Securities Exchange</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year Listed</td>
<td>2001</td>
</tr>
<tr>
<td>Headquarters</td>
<td>Fremont, CA and Adelaide, Australia</td>
</tr>
<tr>
<td>Ticker</td>
<td>ELX</td>
</tr>
<tr>
<td>Last reported revenues</td>
<td>US$30 million (6 months to 31 December 2017)</td>
</tr>
<tr>
<td>Last reported annual revenues</td>
<td>US$56 million (12 months to June 2017)</td>
</tr>
<tr>
<td>Last reported earnings</td>
<td>US$(0.7)m EBITDA loss (6 months to 31 December 2017)</td>
</tr>
<tr>
<td>Net tangible assets</td>
<td>US$53 million (including cash US$19 million)</td>
</tr>
<tr>
<td>Market capitalization as at March 10, 2018</td>
<td>US$93 million</td>
</tr>
</tbody>
</table>
GLAUCOMA DEVICES MARKET - GROWTH

CURRENT MARKET\(^1\)
(in US millions)

- **MIGS**
  - US$263m
- **PHARMA**
  - US$4600m

US$4.9 billion per annum\(^*\)

**US$5.3 billion per annum\(^*\)**

PROJECTED MARKET IN 2022\(^1\)
(in US millions)

- **MIGS**
  - US$1423m
- **PHARMA**
  - US$3900m

\(^*\) MIGS market includes SLT.

1. MarketScope 2017 Glaucoma Surgical Devices, Early to Moderate Glaucoma Therapy Devices
GLAUCOMA DEVICES MARKET - GROWTH

GLAUCOMA
is characterized by high intraocular pressure (IOP)

LEADING CAUSE
of irreversible blindness

82 MILLION
people worldwide with glaucoma

Growth in glaucoma device demand is driven by emerging recognition of poor patient compliance and side effects associated with medication. The established pharma market is failing to deliver.

PROJECTED MARKET IN 2022¹ (in US millions)

- MIGS*
  - US$1423m
- PHARMA
  - US$ 3900m

US$5.3 billion per annum*

* MIGS market includes SLT.

¹ MarketScope 2017 Glaucma Surgical Devices, Early to Moderate Glaucoma Therapy Devices
GLAUCOMA DEVICE MARKET:
ELLEX IS CURRENTLY RANKED NO. 2

SHARE OF REVENUE FROM DEVICES IN 2018 FOR EARLY-MODERATE STAGE GLAUCOMA THERAPY*
(Estimated annual US$m revenue)

- GLAUKOS: 26.3%
- ELLEX: 17%
- ALCON: 10%
- ALLERGAN: 9.9%
- LUMENIS: 14.3%
- OTHER MIGS: 26.3%
- OTHER SLT: 30%

US$262.5 million per annum*

*Market Scope 2017 Glaucoma Surgical Device Report estimates for Alcon and Allergan
Public information from Glaukos
Public information from Ellex
Stockmarket analyst estimates for Ellex
ELLEX RESTORATIVE GLAUCOMA THERAPY

ELLEX iTrack™
A minimally invasive glaucoma surgery (MIGS) device that dilates, purges and rejuvenates Schlemm’s canal to restore the ocular drainage outflow system.

ELLEX tango™
A very short pulse of (SLT) laser light that rejuvenates the trabecular meshwork to facilitate flow into Schlemm’s canal, restoring the ocular drainage outflow system.

ELLEX IS THE ONLY COMPANY TO OFFER A COMPREHENSIVE REJUVENATION APPROACH TO RESTORE IOP.
GLAUCOMA: DATED PARADIGM

1. MEDS
   - Daily administration of eye drops.
   - < 50% patient compliance.
   - Side effects include stinging, blurred vision, eye redness, low blood pressure, reduced pulse rate.

2. ALT
   - Argon Laser Trab (ALT) coagulates tissue; performed after meds.
   - Can be performed only once per patient, due to permanent scarring of the trabecular meshwork.

3. SURGERY
   - Trabeculectomy – permanent opening in the eye with drugs to keep it from healing (bleb).
   - 50% failure rate at five years.
   - High post surgical infection risk
   - Significant post-operative patient management burden.

4. OCULAR IMPLANT
   - Highly invasive.
   - Reserved for end-stage disease only.

This is the dated treatment paradigm for only Primary Open-Angle Glaucoma (POAG) and Angle Closure Glaucoma (ACG).
With a move away from medication to SLT as first-line treatment, and the introduction of a new class of surgery, MIGS – Minimally Invasive Glaucoma Surgery – the treatment paradigm for glaucoma is changing significantly.

Ellex is the only company to offer an SLT laser (Ellex Tango) and a MIGS device (Ellex iTrack) – the treatment synergies of which are significant.

ELLEX iTrack™ AND ELLEX tango™ ARE COMPLEMENTARY REJUVENATIVE THERAPIES THAT LOWER IOP.
**MISSION:** DISPLACE MEDICATIONS WITH ELLEX tango™

ELLEX tango™ is the best primary therapy for both POAG* and ACG* in place of medications.

- **Highly Effective**
  - RESULTS OF PROSPECTIVE, RANDOMIZED STUDY

- **30%**
  - AVERAGE IOP REDUCTION OVER FIVE YEARS

- **High benefit-risk ratio**
  - FREE OF THE SYSTEMIC AND OCULAR SIDE EFFECTS ASSOCIATED WITH DROPS


*POAG = Primary Open-Angle Glaucoma and ACG = Angle Closure Glaucoma

- Recognized as global leader in SLT
- 50% market share
- Opportunity to increase market penetration
Ellex iTrack™ is a restorative MIGS. It is a highly viable option when primary treatment options fail and is the best choice for combined cataract surgery.

**MISSION: ELLEX iTrack™ FOR EARLIER INTERVENTION**

- Comprehensive
  - Targets entire outflow pathway

- **30%**
  - Average reduction in mean IOP

- **50%**
  - Reduction in medication burden

- Patented illuminated iTrack device
- High margin consumable product
- Adjunct to other MIGS

ELLEX tango™
- First-line therapy
- Best choice for rejuvenative light therapy
- Quick and easy outpatient procedure
- Simple post-op follow-up
- Sustained IOP reduction

ELLEX iTrack™
- High safety profile – provides for earlier surgical intervention in cases of mild-moderate glaucoma
- Simple post-op follow-up

TRADITIONAL SURGERY
- 50% failure rate at five years.
- Significant post-operative burden: blebs are costly and difficult to manage.

OCULAR IMPLANT
- Highly invasive.
- Reserved for end-stage disease only.

GLAUCOMA NEW PARADIGM

EARLY  MILD-MODERATE  SEVERE  ADVANCED
ELLEX iTrack™

Revitalizes the natural outflow pathways:
• Employs circumferential (360°) catheterization of Schlemm’s canal combined with gentle viscodilation.
• Spares conjunctival manipulation.

Unlike stent-based MIGS, ELLEX iTrack™ does not leave anything behind.

Addresses all aspects of the ocular outflow system:
• Site of glaucoma resistance is not known.
• With stent-based MIGS there is a risk that the area of blockage will be missed or sub-optimally treated.

Based on principles of angioplasty

• Patented, single-use microcatheter
• Distinguished from MIGS competitors as follows:
  1. iTrack™ can be used and reimbursed in USA without concurrent cataract surgery.
  2. Superior to other MIGS that comprise a single-point stent that either bypasses or penetrates Schlemm’s canal; iTrack™ clears Schlemm’s canal and opens the collector channels.
**ELLEX iTrack™ AS AN ADJUNCT MIGS**

Ellex iTrack™ can stand alone – or be performed in conjunction with other MIGS.

“ABiC with iTrack can be performed subsequent to SLT, stent placement, and even trabeculectomy. It is approved and reimbursable for all grades of glaucoma, whether or not performed in conjunction with cataract surgery...”.

Prof. David Lubeck, MD, PhD.
Assistant Clinical Professor of Ophthalmology, UIC Eye Center, Chicago, Illinois

| iTRACK | • TARGETS ENTIRE OUTFLOW SYSTEM  
<table>
<thead>
<tr>
<th></th>
<th>• MILD-MODERATE AND SEVERE GLAUCOMA</th>
</tr>
</thead>
</table>
| iStent (Glaukos) | • TARGETS A SINGLE POINT ONLY IN SCHLEMM’S CANAL  
|        | • MILD-MODERATE GLAUCOMA |
| CyPass (Alcon) | • TARGETS SUB-CONJUNCTIVAL SPACE  
|        | • SEVERE/ADVANCED GLAUCOMA |
| XEN (Allergan) | • TARGETS SUPRACILIARY SPACE  
|        | • SEVERE/ADVANCED GLAUCOMA |
ELLEX iTrack™ PERFORMED AFTER GLAUKOS iSTENT

Source: Prof. David Lubeck, MD, PhD. Assistant Clinical Professor of Ophthalmology, UIC Eye Center, Chicago, Illinois
ELLEX iTrack™ GLOBAL USAGE

- 6000 procedures performed globally in 6 months to 31 December 2017
  - 50% usage in USA, growing at 64% year-on-year
- Good growth in markets outside the US and good initial sales into China, where Ellex iTrack™ has CFDA approval
- Continued USA sales force recruitment and additional marketing key growth drivers
ELLEX iTrack™ CLINICAL DATA AT 2 YEARS

% REDUCTION IN IOP AND MEDICATION USE COMPARED TO BASELINE

<table>
<thead>
<tr>
<th></th>
<th>ALL EYES (n=75 pre-op)</th>
<th>PHACO+ ABiC (n=34 pre-op)</th>
<th>STANDALONE ABiC (n=41 pre-op)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12-month</td>
<td>24-month</td>
<td>12-month</td>
</tr>
<tr>
<td>n (eyes)</td>
<td>73</td>
<td>33</td>
<td>3</td>
</tr>
<tr>
<td>Reduction in IOP (%)</td>
<td>33.68%</td>
<td>39.06%</td>
<td>33.24%</td>
</tr>
<tr>
<td>Reduction in number of medications (%)</td>
<td>60.75%</td>
<td>70.15%</td>
<td>67.05%</td>
</tr>
</tbody>
</table>

Data courtesy of Mark J. Gallardo, MD. Data unpublished.
SLT, ELLEX tango™

SLT is a highly effective first-line therapy. It is also effective as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail.

- SLT should be considered the least invasive MIGS.
- SLT can be applied both before and after other MIGS to stave off medication – and filtration surgery – for longer.
- SLT does not affect outcomes of future surgery or medication use - can be used earlier in treatment paradigm.
- SLT is not ALT; SLT agitates cells – it does not destroy them. Whereas ALT denatures and may preclude the use of MIGS, SLT pairs seamlessly with other MIGS.
Opportunity to increase market penetration of SLT as a first-line therapy in both developed and developing markets.

- Ellex is recognised as the global leader in SLT laser technology - holds approximately 50% market share (1)
- Proven efficacy plus good financial returns to physicians
- Experience in Australia is that approx. 40% of all ophthalmologists will adopt SLT
- If Australian penetration levels are achieved globally, opportunity equates to 20,000 units at average sell price of US$50,000 per unit.

(1) MarketScope 2017
Alongside its role in treating glaucoma, SLT with Ellex tango™ can also provide powerful insight into glaucoma patients’ pathology.

• Since SLT primarily addresses the trabecular meshwork (TM), a successful SLT procedure implies that the primary blockage is located in the TM.

• Not only is this helpful in better understanding the patient’s pathology, but it can also assist with the selection of future treatment options, including MIGS.

• The role of SLT as a diagnostic aid further supports its role as a primary therapy.
ELLEX REVENUE AND GROWTH

ELLEX iTrack™ REVENUE GROWTH (US$ MILLIONS)

ELLEX GLAUCOMA DEVICE GROWTH (US$ MILLIONS)
ELLEX GROWTH DRIVERS

1. Increased uptake of ELLEX tango™ as primary therapy
2. Increased market penetration of ELLEX iTack™ MIGS device
3. Exploit synergies between ELLEX tango™ and ELLEX iTack™

1. Clinical trial expected to be completed in FY19
2. Leverage existing global sales channel to commercialize ELLEX 2RT® in key markets
THANK YOU

www.glaucoma-SLT.com
www.glaucoma-iTrack.com